Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment

Acta Haematol. 2003;110(4):224-6. doi: 10.1159/000074235.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Adult
  • Chelating Agents / administration & dosage
  • Chelating Agents / therapeutic use
  • Child
  • Deferiprone
  • Deferoxamine / administration & dosage
  • Deferoxamine / therapeutic use*
  • Humans
  • Immunophenotyping
  • Pyridones / administration & dosage
  • Pyridones / therapeutic use*
  • beta-Thalassemia / drug therapy*
  • beta-Thalassemia / immunology*

Substances

  • Chelating Agents
  • Pyridones
  • Deferiprone
  • Deferoxamine